WUXI BIO and Candid Therapeutics have reached a research service collaboration on T-cell bridging trispecific antibodies.

Breakings · Jan 7 00:24

WUXI BIO announced today that it has reached a research service cooperation agreement with Candid Therapeutics (referred to as Candid). Candid is a clinical-stage biotechnology company dedicated to becoming a leader in T cell engager (TCE) therapies for autoimmune and inflammatory diseases. According to the agreement, Candid will hold global rights to a trispecific antibody that is in the preclinical development stage. This antibody is based on WUXI BIO's universal multi-specific antibody patent technology platform, WuXiBody. WUXI BIO will receive an upfront payment and will be eligible to receive development and sales milestone payments, totaling up to 0.925 billion USD, as well as sales royalties after the product is launched.

The translation is provided by third-party software.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.